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Abstract
Background: Prion diseases are fatal neurodegenerative disorders with no effective therapy currently available.
Accumulating evidence has implicated over-activation of P2X7 ionotropic purinergic receptor (P2X7R) in the progression
of neuronal loss in several neurodegenerative diseases. This has led to the speculation that simultaneous blockade of this
receptor and prion replication can be an effective therapeutic strategy for prion diseases. We have focused on Brilliant Blue
G (BBG), a well-known P2X7R antagonist, possessing a chemical structure expected to confer anti-prion activity and
examined its inhibitory effect on the accumulation of pathogenic isoforms of prion protein (PrPres) in a cellular and a mouse
model of prion disease in order to determine its therapeutic potential.
Principal Findings: BBG prevented PrPres accumulation in infected MG20 microglial and N2a neural cells at 50% inhibitory
concentrations of 14.6 and 3.2 mM, respectively. Administration of BBG in vivo also reduced PrPres accumulation in the
brains of mice with prion disease. However, it did not appear to alleviate the disease progression compared to the vehicle-
treated controls, implying a complex role of P2X7R on the neuronal degeneration in prion diseases.
Significance: These results provide novel insights into the pathophysiology of prion diseases and have important
implications for the treatment.
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Introduction
Prion diseases are fatal, transmissible, and progressive neuro-
degenerative disorders that include Creutzfeldt–Jakob disease
(CJD) and Gerstmann–Straussler–Scheinker syndrome (GSS) in
humans, bovine spongiform encephalopathy (BSE) in cattle,
scrapie in sheep and goats, and chronic wasting disease in deer.
The neuropathology is characterized by brain vacuolation,
astrogliosis, microglial activation, neuronal loss, and progressive
accumulation of a misfolded protease-resistant isoform (PrPres) of
the host-encoded protease-sensitive prion protein (PrPsen) [1]. The
conversion of PrPsen to PrPres is believed to be the key event in
prion pathogenesis. Until date, the precise molecular mechanisms
underlying glial activation and neuronal dysfunction remain
unknown and there are no effective treatments for prion diseases.
P2X7 ionotropic purinergic receptor (P2X7R) is an ATP-gated
ion channel believed to be associated with the regulation of both
neuronal death and survival. P2X7R is abundantly expressed in
microglia [2] and to a lesser extent in astrocytes [3], oligoden-
drocytes [4], and the presynaptic terminals of neurons [5].
Accumulating evidence suggests that the P2X7R signal pathways
are involved in the modulation of glutamate release from
presynaptic terminals of neurons and astrocytes [6–8], resulting
in synapse dysfunction and glutamate-mediated excitotoxicity.
Furthermore, signaling through P2X7R plays a crucial role in the
activation and proliferation of microglia [9]. After activation of
P2X7R by ATP, activated microglia release various proinflam-
matory cytokines (e.g., IL-1b) and other bioreactive substances,
leading to neuronal damage [10–12]. In addition to its deleterious
effects, P2X7R activation also stimulates the release of c-
aminobutyric acid from nerve terminals [6] and production of
endocannabinoids in astrocytes and microglia [13,14], both of
which are transmitters with neuroprotective roles. P2X7R
activation also involves a neuroprotective effect through activation
of ERK1/2 signaling [15]. Thus, P2X7R activation can have both
protective and detrimental effects on neurons.
P2X7R expression is upregulated in the brains of patients with
and in various animal models of neurodegenerative diseases,
including multiple sclerosis and Alzheimer’s and Huntington’s
diseases [16–19]. In addition, we recently reported that P2X7R is
upregulated in a mouse model of prion disease [20]. Although it
remains debatable whether P2X7R plays a beneficial or
detrimental role in these diseases, a number of studies illustrate
that the blockade or deficit of P2X7R has neuroprotective effects
in animal models of multiple sclerosis [4], Huntington’s disease
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data regarding the role of P2X7R in prion diseases is lacking, the
simultaneous blockade of this receptor and inhibition of prion
replication may alleviate the progression of prion diseases.
One candidate for a therapeutic compound that possess such
combined drug actions is Brilliant Blue G (BBG), a well-known
P2X7R antagonist; BBG can cross the blood–brain barrier, has
low toxicity, and exhibits therapeutic effects in several animal
models of neurodegenerative diseases [23]. Furthermore, BBG has
a symmetrical bifunctional structure comprising of two moieties
joined via a spacer; this molecular framework is expected to confer
anti-prion activities [24] as in the case of anti-prion compounds
such as Congo red [25], suramin [26], and curcumin [27]. These
properties prompted us to assay BBG for its ability to inhibit
PrPres accumulation.
In this study, we examined the inhibitory effect of BBG on
PrPres accumulation in a cellular and a mouse model of prion
disease and we also investigated the therapeutic potentials of BBG
due to its P2X7R antagonistic and predicted anti-prion activities.
We found that BBG inhibited PrPres accumulation in prion-
infected microglial and neural cell lines, possibly via down-
regulation of cell-surface PrPsen. BBG prevented PrPres accumu-
lation in the brain of prion-infected mouse. However, BBG did not
appear to alleviate the disease progression.
Materials and Methods
Reagents and antibodies
BBG (Ultra Pure Grade) was obtained from AnaSpec (San Jose,
CA, USA) and all other reagents were purchased from (Sigma-
Aldrich, St. Louis, MO, USA) unless otherwise specified. The
following antibodies were used in this study: anti-prion protein
(PrP) SAF32 monoclonal antibody (mAb) (SPI Bio, Montigny le
Bretonneux, France); anti-PrP mAbs 3H2, 4E10, and T2 [28,29];
anti-P2X7R rabbit polyclonal antibody (Sigma, P8232); anti-glial
fibrillary acidic protein (GFAP) mAb (Sigma, G3893); anti-b-actin
mAb (Sigma, A2228), anti-synaptophysin 1 mAb (Synaptic
Systems, Gottingen, Germany); anti- ionized calcium binding
adaptor molecule 1 (Iba1) rabbit polyclonal antibody (Wako Pure
Chemical, Osaka, Japan); and HRP-conjugated goat anti-mouse
and anti-rabbit antibodies (Calbiochem, San Diego, CA, USA).
Cell culture conditions and inhibition assay of PrPres
accumulation
MG20 cells persistently infected with mouse-adapted scrapie
ME7 prion (ScMG20 cells) [30] were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% heat-inacti-
vated fetal bovine serum, 10 mM 2-mercaptoethanol, 10 mg/ml
insulin,100 units/ml penicillin, 100 mg/ml streptomycin sulfate at
37uC with 5% CO2. N2a cells were obtained from American Type
Culture Collection. N2a cells persistently infected with mouse-
adapted scrapie Chandler prion (ScN2a) were cultured in Opti-
MEM supplemented with 10% heat-inactivated fetal calf serum at
37uC with 5% CO2.
The cells were detached by the addition of 5 mM EDTA in
phosphate-buffered saline (PBS) with gentle pipetting, and cell
density was determined by cell counting using an hemocytometer.
ScMG20 and ScN2a cells were plated in 6-well plates (1610
5
cells/well) and allowed to settle for 1 h or 1day prior to the
treatment with an antagonist, respectively. Cells were treated with
BBG (0.6–60 mM) or without BBG, oxidized-ATP (25–150 mM;
an irreversible inhibitor of P2X7R), or A438079 (4.5–36 mM; an
inhibitor of P2X7R) for 3 days, after which the accumulation of
PrPres was detected by western blotting of the lyzed cells.
Cell viability
Cytotoxicity was determined using the WST-8 assay (Cell
Counting Kit-8; Dojindo Lab, Kumamoto, Japan). ScMG20 cells
were plated in the wells of a 96-well plate (3610
3 cells/well) and
incubated with the appropriate concentration of one of the three
antagonists for 3 days prior to the WST-8 assay, according to the
manufacturer’s instructions. The treatment with each substance
was performed in triplicate. The percentage cell viability was
calculated with reference to that of untreated cells incubated with
WST-8 (100%).
SDS-PAGE and western blotting
Cells were washed once with PBS and then lyzed in an ice-cold
lysis buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl,
5 mM EDTA with 0.5% Triton X-100, and 0.5% sodium
deoxycholate. Frozen mice brain or mice spleen tissue was
homogenized in an ice-cold lysis buffer containing 10 mM Tris-
HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA with 0.5% Triton X-
100, 0.5% sodium deoxycholate, and 0.1% SDS. After removal of
insoluble debris by centrifugation at 10,0006g for 2 min, the total
protein concentrations of the samples were measured by the
bicinchoninic acid assay (BCA protein assay; Thermo Fisher
Scientific, Rockland, IL, USA) and equal amounts of protein were
analyzed.
For PrPres detection, cell lysates and tissue homogenates were
digested with proteinase K (20 and 50 mg/ml for the cell tissues
and brain tissues, respectively) for 1 h at 37uC. The reactions were
stopped by the addition of 4 mM Pefabloc (Roche Diagnostics,
Basel, Switzerland). Cell lysates were then ultracentrifuged at
200,0006 g for 1 h in a TLA 55 rotor (Beckman Coulter,
Fullerton, CA, USA) and the resulting pellets were used for further
analysis. The samples were solubilized in LDS-sample loading
buffer (Invitrogen, San Diego, CA, USA) prior to electrophoresis
on 12% NOVEX pre-cast gels (Invitrogen) and electrotransfered
onto Durapore (Millipore, Billerica, MA, USA) polyvinylidene
fluoride membranes. Chemilumi One Super (Nakarai Chemical,
Kyoto, Japan) was used for immunodetection. For quantitation,
blots were imaged with a Fluorchem (Alpha Innotech, San
Leandro, CA, USA) and analyzed with Image Reader software
(AlphaEaseFC; Alpha Innotech) according to the manufacturer’s
instructions. The values were normalized to b-actin as loading
controls.
Degycosylation analysis
For analysis of PrP levels, MG20 cells were incubated with the
indicated concentrations of BBG. After 3 days, cell extracts were
prepared in lysis buffer, and PrP was deglycosylated by treating the
extracts with PNGase F (peptide N-glycosidase F) (New England
BioLabs, Beverly, MA, USA) for 2 h at 37uC as described
previously [30].
Infectivity assay
The infectivity associated with ScMG20 cells was assayed by
intracerebral inoculation into murine PrP-overexpressing (tga20)
mice. ScMG20 cells were harvested for inoculation at serial
passage 5 in the presence or absence of 30 mM BBG. The cells
were suspended in sterile PBS(2), freeze-thawed, and sonicated
before intracranial inoculation (2.5610
4 cells/20 ml/mouse). After
inoculation, the terminally ill mice were sacrificed for western
blotting of the brain tissues. All mice were kept in an air-
conditioned room and fed on standard laboratory food pellets and
water ad libitum.
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Detergent solubility assays were performed as previously
described [26]. MG20 cells treated with or without 30 mM BBG
were lyzed in cold lysis buffer. Postnuclear lysates were ultra-
centrifuged for 1 h at 100,0006 g at 4uC in the presence of
Complete proteinase inhibitor cocktail (Roche) and 1% N-lauryl
sarcosine. PrPsen in the supernatant and pellet fractions was
detected by western blotting.
In vivo BBG treatment
C57BL/6 mice were intracerebrally infected with 20 ml of 10%
homogenate prepared from the brains of either healthy C57BL/6
mice or terminally ill C57BL/6 mice with Fukuoka-1 (FK-1) strain
of murine GSS. Hundred days after infection, mice were treated
intraperitoneally 3 times per week for 3 weeks and 2 times per
week for 4 additional weeks with 500 ml of 100 mg/kg BBG
diluted with 10% ethanol in saline. A control group of GSS-
infected animals was treated with the vehicle only.
Confocal imaging
Cells grown on a 4-well chambered coverglass were incubated
with BBG for 3 days. After rinsing with PBS, the cells were fixed
with 4% paraformaldehyde in PBS for 30 min at room
temperature and then treated with or without 0.5% Triton X-
100 in PBS. After a brief wash with PBS, the cells were incubated
with blocking solution (1% bovine serum albumin, 5% normal
goat serum, and 0.1% Tween 20 in PBS) for 30 min. The primary
antibody directed against PrP (SAF32) was used at a 1:500 dilution
in blocking solution and incubated for 1 h at room temperature.
Cells were subsequently incubated with anti-mouse Alexa Fluor
488-conjugated secondary antibody (Invitrogen) for 1 h. The
chambered coverglass was overlaid with a mounting solution [25%
glycerol, 10% Mowiol (Calbiochem) in 100 mM Tris-HCl,
pH 8.5] and examined with the Zeiss LSM510 inverse laser scan
microscope.
Flow cytometric analysis
Cells grown on 100-mm cell culture dishes were incubated with
30 mM BBG for 3 days. After rinsing with ice-cold PBS, cells were
harvested by pipetting. Next, 2 mg of several anti-PrP antibodies
were pre-labeled using the Zenon PE Mouse IgG Labeling Kit
(Invitrogen), according to the manufacturer’s instructions. Cells
were incubated for 30 min at 4uC with each Zenon-labeled
antibody and washed twice in PBS containing 1% BSA. Following
fixation with 1% paraformaldehyde in PBS, cells were analyzed
with the EPICS XL SYSTEM II flow cytometer (Beckman
Coulter, Miami, FL). Fluorescence of 1.5610
4 cells/antibody was
acquired and analyzed using Flowjo software (Tree Star, Ashland,
OR, USA) to quantify the surface expression of PrP by calculating
the mean fluorescence intensities.
Protein misfolding cyclic amplification (PMCA) assay
Brains from healthy mice and Chandler scrapie-infected mice at
the terminal stage of the disease were minced using the BioMasher
(Nippi) and suspended in a conversion buffer. After removal of
insoluble debris by centrifugation at 4,5006 g for 5 min, the
supernatants were collected. The Chandler brain homogenate was
diluted 1:1000, 1:10000, and 1:100000 with healthy brain
homogenates. Serial dilutions of BBG in PBS were added to the
brain homogenates to obtain final concentrations of 0.6, 6, 60, and
600 mM. The samples were incubated at 37uC with agitation for
30 min and then subjected to a cycle of sonication every hour, as
previously described [31].
Quantitative real-time reverse transcriptase polymerase
chain reaction (Q-PCR) analysis
The mRNA levels were assayed by Q-PCR. Total RNA was
isolated from cells with FastPure RNA Kits and treated on
a column with RNase-free DNase I (Takara, Osaka, Japan). Total
RNA was reverse transcribed using ReverTra Ace (Toyobo,
Osaka, Japan) with random hexamers primers. Diluted reactions
were analyzed with SYBR Premix Ex Taq (Takara) and an ABI
Prism 7500 detection system (Applied Biosystems). PrP mRNA
levels were normalized to those of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). cDNA levels of PrP and GAPDH were
determined relative to standard curves from PCR fragments
amplified by RT-PCR using total RNA and a Q-PCR primer pair.
The slope of the standard and dissociation curves of the products
indicated sufficient PCR quality. The primers used were as
follows: mouse PrP, (forward) 59-ATGGCGAACCTTGGC-
TACTG-39 and (reverse) 59-CCTGAGGTGGGTAACGGTTG-
39; GAPDH, (forward) 59-AGGTCGGTGTGAACGGATTTG-
39 and (reverse) 59-TGTAGACCATGTAGTTGAGGTCA-
GATTTG-39.
Statistical analysis
Values in the figures are expressed as mean 6 SD. To
determine statistical significance, Welch’s t-test for unpaired data
was applied as appropriate. A value of p,0.05 was considered
significant.
Ethics Statement
Procedures involving animal subjects have been approved by
the Institutional Animal Care and Use Committee at the National
Institute of Animal Health (approval ID: 09-44 and 10-005).
Results
BBG inhibits PrPres accumulation and prion replication in
mouse scrapie-infected cells
In the present study, we examined the effects of P2X7R
antagonists on PrPres accumulation in cultured microglial cells
persistently infected with the ME7 murine strain of scrapie
(ScMG20 cells). Cells were treated with one of the three
antagonists: BBG, oxidized-ATP, or A438079. BBG inhibited
PrPres accumulation in a dose-dependent manner, with a 50%
inhibitory concentration (IC50) of approximately 14.6 mMi n
ScMG20 cells (Figs. 1A, 1B). On the other hand, the levels of
PrPres were not reduced following a treatment of cells with
oxidized-ATP or A438079. The toxicity of the P2X7R antagonists
was assessed using the WST-8 metabolic assay (Fig. 1C). ScMG20
cell viability decreased by approximately 20% at the highest
concentration of each antagonist. However, BBG was not toxic at
concentrations required for maximal inhibition of PrPres accu-
mulation. These results suggest that anti-prion activity of BBG was
derived from its molecular frameworks (Fig. 1D), which are
analogous to the anti-prion compounds and not from its P2X7R
antagonistic activity.
To determine the effects of BBG on prion replication, bioassays
of ScMG20 cells treated with or without BBG were conducted.
ScMG20 cells were serially passaged up to 5 times in the presence
of 30 mM BBG. The level of PrPres in ScMG20 cells became
undetectable after 3 passages with BBG (Fig. 1E insert). In-
oculation of tga20 mice (n=10) with untreated ScMG20 cells
resulted in a mean survival time of 151.5627.8 days (mean 6 SD).
On the other hand, mice inoculated with BBG-treated cells
showed a prolonged incubation period of the disease, with 6 out of
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37896Figure 1. BBG prevents PrPres and prion accumulation in ScMG20 cells. (A) Western blotting of the levels of PrPres and P2X7 receptor
proteins. ScMG20 cells were mock-treated or treated with each tested drug at the indicated concentrations for 3 days. PrPres and P2X7 receptor
protein levels in ScMG20 cells were measured by western blotting. Molecular mass standards (kDa) are indicated on the right. Membranes were
probed with anti-b-actin to correct any possible deviation in the protein concentration. (B) The densitometric measurement of PrPres and P2X7
receptor protein signals detected in the blots. Band intensity for PrPres and P2X7 receptor proteins was measured, normalized using the values
obtained for b-actin intensities, and expressed as percentage relative to the 0 mM concentration points described in the Materials and Methods
section. Results are expressed as the mean 6 SD of three different experiments. Significant differences at a p,0.05 (
*) and 0.01 (
**) between treated
and untreated cells are indicated. (C) The effects of P2X7 antagonists on viability of ScMG20 cells. Cell viability determined by the WST-8 assay is
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days after inoculation. We also examined the efficacy of anti-prion
activity of BBG using neuronal derivative N2a cells infected with
the Chandler murine strain of scrapie (ScN2a). BBG also
prevented PrPres accumulation in ScN2a cells, with an IC50 of
3.2 mM (data not shown).
BBG depletes cells of PrP and modifies its cellular
localization
The level of endogenous PrPsen influences the rate of
replication of prions [32] and a reduction in its level abrogates
PrPres formation [33]. To examine whether the reduction of
PrPres by BBG was mediated by the suppression of PrPsen, the
PrPsen level in uninfected MG20 cells treated for 3 days with
various concentrations of BBG was ascertained. Cell lysates not
treated with proteinase K (PK) were subjected to western blotting,
and the total PrPsen (full-length PrPsen plus C-terminal fragments)
levels were determined after the removal of carbohydrates by
PNGaseF (Fig. 2A). At a concentration of 60 mM, BBG
significantly reduced the total PrP levels and mediated a reduction
in the ratio of full-length PrPsen to total PrPsen, suggesting
a preferential decrease in full-length PrPsen (Fig. 2B).
To determine whether BBG affected PrPsen synthesis, we
examined the expression levels of PrPsen mRNA in MG20 cells
treated with or without 30 mM BBG by Q-PCR. The PrPsen
expression level was calculated as the ratio of the number of
PrPsen copies to the number of GAPDH copies. The mean
expression level of PrPsen in BBG-treated cells was 0.02860.001
(mean 6 SD of 3 independent experiments), which was slightly
lower than that of 0.03160.001 in untreated cells. This result
suggests that the reduction of PrPsen might be, at least in part,
associated with the downregulation of its expression.
PrPsen cycles between the cell surface and the endosomal
compartments, and PrPres formation is postulated to occur in this
pathway [34–38]. To determine whether BBG treatment can
influence PrPsen localization, the cell-surface expression of PrPsen
was investigated by fluorescence-activating cell sorting (FACS)
analysis. Mabs 3H2, which reacts with linear amino acid epitope
38–53, was used to detect full-length PrPsen and Mabs T2, which
reacts with the discontinuous epitope spanning amino acids 132–
156, was used to assess the total PrPsen. BBG-treated cells showed
a decrease in the level of full-length PrPsen levels on the cell
surface as compared with untreated cells (Fig. 2C); this result was
consistent with the western blotting results.
The effect of BBG on the cellular localization of PrPsen was also
examined by confocal microscopy. To detect only full-length
PrPsen, we used SAF32, which reacts with linear amino acid
epitopes 59–89. In mock-treated non-permeabilized cells, full-
length PrPsen was found to be localized at the cell surface. In the
presence of BBG, a marked decrease of full-length PrPsen at the
cell surface was detected (Fig. 2D). These results demonstrate that
BBG interrupts the cell-surface expression of PrPsen.
Misfolded PrPsen is undetectable in BBG-treated cells
Previous studies have demonstrated that several anti-prion
compounds cause misfolding of PrPsen, as evidenced by the
relative detergent insolubility and formation of intracellular
aggregates, resulting in the downregulation of surface PrPsen by
altering its distribution inside the cell or inducing its rapid
degradation (e.g., dextran sulfate, pentosan polysulfate, and
epigallo catechin gallate) [26,39,40]. Thus, it is possible that the
reduction in full-length PrPsen levels at the surface of BBG-treated
cells is due to the misfolding of PrP.
To investigate this possibility, MG20 cells were treated with or
without 30 mM BBG followed by a detergent solubility assay. Cells
were lyzed in a detergent buffer, and the presence of PrPsen in the
detergent-soluble and detergent-insoluble fractions was analyzed
by western blotting. PrPsen was detected in both the detergent-
soluble and, to some extent, the detergent-insoluble fractions
(Fig. 3A). There was no significant difference in the level of
detergent insoluble PrPsen in the presence or absence of BBG.
Furthermore, the cellular localization of PrPsen in BBG-treated
cells was visualized by indirect immunofluorescence of permea-
blized cells. Similarly, there was no observable difference in the
intracellular localization of PrPsen in presence or absence of BBG
(Fig. 3B).
BBG does not affect PrPres amplification in vitro.
To assess the possibility of the direct influence of BBG on PrPres
formation, we utilized the PMCA technique [41]. PMCA was
performed with chandler-infected mouse brain homogenate as the
seed in the presence of BBG. For evaluating the amplification of
PrPres after the PMCA reaction, the PK-resistant bands were
semi-quantified by densitometric analysis. The presence of BBG in
the PMCA reaction buffer did not significantly affect the
amplification of PrPres except at an extremely high concentration
(600 mM) (Fig. 4). These results suggest that BBG exert its effect on
PrPres accumulation via complex cellular processes.
BBG reduces the cerebral accumulation of PrPres but
does not prolong the survival time of murine GSS-
infected mice
Lastly, we tested whether BBG could affect prion disease and
prevent the disease progression during the later stages of infection.
Hundred days after intracerebral inoculation with a high dose of
FK-1 murine GSS strain (at 60% disease duration), mice were
intraperitoneally treated with 100 mg/kg BBG 3 times per week
for 3 weeks. In order to assess the effect of BBG on the
pathological brain changes, some of the treated mice (n=3) were
euthanized and their brain homogenates were subjected to semi-
quantitative western blotting at 121 days after infection (Fig. 5A,
5B). The remaining mice (n=7) were continuously treated with
100 mg/kg BBG 2 times per week for a total of 7 weeks. In the
brains of the mice treated with BBG for 3 weeks, the PrPres signal
obtained using mAb T2 was reduced by 43% compared with that
in the vehicle-treated control animals (p,0.01).
It has been shown that in murine prion disease, impaired
synaptic protein, synaptic loss, and gliosis occur at an early stage
[42–46]. Thus, the extent of synaptic loss and gliosis usually
reflects the severity of the prion disease. Consistent with these
reports, western blotting of the brain homogenates from mice
infected with FK-1 strain demonstrated that synaptophysin levels
shown. The absorbance values are expressed as mean 6 SD relative to the absorbance values of untreated control ScMG20 cells from 3 independent
experiments. Significant differences at p,0.05 (
*) and 0.01 (
**) between treated and untreated cells are indicated. (D) Structures of Brilliant Blue G. (E)
Kaplan–Meier survival analysis of tga20 mice inoculated with ScMG20 cells treated with or without BBG. tga20 mice were inoculated intracerebrally
with ScMG20 cells in 5 serial passages in the presence or absence of 30 mM BBG. Animals that received BBG-treated cells (BBG+, broken line) showed
longer survival times compared to those that received untreated cells (BBG2, solid line). The inset picture shows that the kinetics of PrPres levels in
ScMG20 cells serially passaged 5 times in the presence or absence of 30 mM BBG. The numbers above the lanes indicate the passage number.
doi:10.1371/journal.pone.0037896.g001
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were elevated by approximately 310% and 230%, respectively,
compared with those in mock-treated control mice. In accordance
with a previous report [20], P2X7R levels were elevated by
approximately 30% in diseased mice.
Surprisingly, in mice infected with FK-1 and treated with BBG,
synaptic loss (synaptophysin marker) and astrogliosis (GFAP
Figure 2. BBG depletes cells of PrPsen and mediates decrease in full-length PrPsen on cell surface. (A) Western blotting of the levels of
PrPsen Uninfected MG20 cells were treated with or without 30 mM BBG for 3 days. PrPsen protein levels in MG20 cells were measured by western
blotting. Molecular mass standards (kDa) are indicated on the left. The locations of full-length (F) and N-terminal truncated PrPsen (C1) are indicated.
Membranes were probed with anti-b-actin to correct for any possible deviation on protein concentration. (B) The densitometric measurement of
PrPsen signals detected in the blots after deglycosylation. The signals of PrPsen from BBG-treated cells are expressed as percentage of the signals
from untreated cells (left panel). The signals of full-length PrPsen band intensities are expressed as a percentage of the signals from total PrPsen (full-
length PrPsen plus C-terminal fragments) (right panel). Each bar indicates the mean values (6SD) of at least three independent experiments.
Significant differences at p,0.05 (
*) and p,0.01 (
**) between BBG and untreated cells are indicated. (C) Fluorescence-activated cell sorting analysis of
cell-surface expression levels of total PrPsen and full-length PrPsen of MG20 cells. The histograms depict the cell-surface expression in non-
permeabilized cells incubated with 30 mM BBG for 3 days. FL2 represents the fluorescence intensity in BBG-treated cells (solid line) and in the
untreated cells (dashed line), plotted against the number of cells (events). For each cell population, 10,000 events were measured. Mabs 3H2 was
used for detection of full-length PrPsen (blue line), and Mabs T2 was used for detection of the total PrPsen (red line) on the cell surface. (D) Confocal
fluorescence microscopic analysis of full-length PrPsen on the cell surface of MG20 cells. Cells were incubated with or without 30 mM BBG for 3 days.
MG20 cells growing on cover glasses were fixed with 4% paraformaldehyde. Confocal fluorescent images (left panels) and Nomarski differential
interference contrast images (right panels) were obtained. Scale bar, 20 mm.
doi:10.1371/journal.pone.0037896.g002
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apparent reduction in the levels of PrPres. Microgliosis (Iba1
marker) tended to decrease, however the reduction was not
significant. P2X7R levels were decreased by approximately 20%.
As a BBG-treatment control, we examined levels of PrP, GFAP,
Iba1 and synaptophysin in the brains of mock-infected mice
treated with vehicle or BBG (100 mg/kg, 3 times per week for 3
weeks). No statistically significant differences in these protein levels
between vehicle and BBG treated animals were observed,
suggesting no detectable detrimental effect of BBG in healthy
animals at this dosage (data not shown).
In the infected mice treated with BBG for 7 weeks, no
significant delay in disease progression was observed (Table 1). In
addition, the level of PrPres did not differ significantly between the
BBG- and vehicle-treated mice at the end of the study (data not
shown). These results suggest that BBG administration slows down
PrPres accumulation in the brains, but has no therapeutic efficacy
in a mouse model of GSS during the later stages of infection.
Discussion
We showed here that BBG, a P2X7R antagonist, prevented
PrPres accumulation in prion-infected MG20 microglial (IC50
14.6 mM) and N2a neural (IC50 3.2 mM) cell lines. In vivo
administration of BBG, which was predicted to exert both anti-
prion and P2X7R antagonistic activities, reduced PrPres accumu-
lation in the brains of mice with prion disease, but it did not
appear to alleviate the disease progression.
Among the three P2X7R antagonists examined, only BBG
inhibited PrPres accumulation in a dose-dependent manner and
reduced prion infectivity in cultured cells. These results suggest
that its anti-prion activity was derived from its molecular
frameworks, which are analogous to the well-known anti-prion
compounds, such as Congo red, suramin, and curcumin, and not
from its P2X7R antagonistic activity.
Several mechanisms can account for the effect of BBG on prion
replication. We propose that BBG mediated the removal of PrPsen
Figure 3. BBG does not induce formation of the detergent-insoluble PrPsen and the intracellular aggregated PrPsen. (A) Insoluble
PrPsen detection in MG20 cells by detergent solubility assay. After incubation with or without 30 mM BBG for 3 days, cells were lyzed and postnuclear
lysates were adjusted to 1% N-lauryl sarcosyl and ultracentrifuged for 1 h at 100,0006 g. PrPsen present in the detergent-soluble (sup) and
detergent-insoluble (ppt) fractions was analyzed by western blotting using monoclonal antibody T2. (B) Confocal fluorescence microscopic analysis of
permeabilized MG20cells. Cells were incubated with or without 30 mM BBG for 3 days. MG20 cells growing on cover glasses were fixed with 4%
paraformaldehyde and incubated with 0.1% Triton X-100. Confocal fluorescent images (left panels) and Nomarski differential interference contrast
images (right panels) were obtained. Scale bar, 20 mm.
doi:10.1371/journal.pone.0037896.g003
Figure 4. PrPres amplification in the presence of BBG by PMCA. (A) Western blotting of PrPres amplified by PMCA. The brain homogenates
from mice with Chandler scrapie were added to normal mice brain homogenates to prepare final dilutions of 1:1000. PMCA was performed with BBG
at indicated concentrations. After PK digestion, PrPres was detected by immunoblot with Mab T2. (0) represents samples without BBG, PMCA(2)
represents samples without amplification and seed(2) represents samples for which PMCA was performed but without seed inoculumn. (B)
Densitometric analysis of PK-resistant PrP signals in panel A. The signals of PrPres band intensities are expressed as a percentage of the PrPres signals
from non-treated (0) cells. Each bar indicates the mean values (6SD) of at three independent experiments.
doi:10.1371/journal.pone.0037896.g004
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formation within the endocytic pathway. Numerous studies have
shown that perturbation of PrPsen cellular trafficking results in
inhibition of PrPres formation, indicating that PrPres formation
happens either on the cell surface or along the endocytic pathway
[34–38,47]. The manner in which BBG reduces the cell-surface
PrPsen remains unclear. One possibility is that BBG might
influence PrPsen synthesis. In uninfected MG20 cells, endogenous
PrPsen levels were significantly reduced after incubation with
BBG. In addition, there was a slight downregulation of PrPsen at
the mRNA levels, which might explain the suppression of the cell-
surface PrPsen.
Alternatively, BBG may directly interact with PrPsen on the cell
surface or with other cellular components that influence PrPsen
trafficking and accelerate the endocytosis of the cell-surface
PrPsen. Several sulfated glycans decrease the amount of the cell-
surface PrPsen by enhancing its rate of endocytosis through an
unidentified mechanism associated with their binding to the N-
terminal region of PrP, which is rich in basic amino acids and
contains a consensus site for heparin and other sulfated glycans
[40]. In addition, the conformational change or oligomerization of
PrPsen at the cell surface induced by epigallocatechin gallate and
copper lead to downregulation of cell-surface PrPsen [39,48].
Although a direct interaction between BBG and PrP remains to be
confirmed, it is conceivable that the binding of BBG to the
polybasic N-terminal of PrPsen could lead to its internalization
since the interaction of BBG with proteins is known to be mediated
by basic and aromatic amino acids [49]. On the other hand,
a BBG-induced conformational change in PrPsen is unlikely since
we did not detect structural alterations of PrPsen in the presence of
BBG, which are characterized by the relative detergent insolubility
and formation of intracellular aggregates.
The third possibility regarding the BBG-mediated reduction of
cell-surface PrPsen is the enhanced degradation of PrPsen. The
reduction of PrPsen levels can be mediated by induced lysosomal,
proteasomal, and autophagic degradations of PrPsen under certain
conditions [26,50,51]; there were not evaluated in this study.
Whether BBG accelerates the degradation of PrPsen remains to be
determined.
The anti-prion activity of BBG did not appear to relate to
a destabilization of pre-existing PrPres aggregates. Incubation of
the cell lysates with BBG before PK treatment did not reduce
PrPres band intensity (data not shown). In addition, BBG did not
significantly modify PrPres in the brain homogenates in a PMCA
reaction. This observation excludes the possibility that BBG
modifies the western blotting detection of PrPres due to an artifact.
Figure 5. BBG prevents cerebral PrPres formation but not prevents disease progression. (A) Western blotting performed on the brain
homogenates of Fukuoka-1 (FK-1) strain of murine GSS infected C57/BL6 mice treated with 100 mg/kg BBG for 3 times per week intraperitoneally for
3 weeks. The control mock and FK-1 infected animals were treated with the vehicle only. Membranes were probed with antibodies against indicated
antigens. (B) Densitometric analysis of marker proteins in panel A. Each bar represents the average ratio from triplicate samples with mock-infected
mice as standard. Significant differences at a p,0.05 (
*) between the BBG- and vehicle-treated animals are indicated.
doi:10.1371/journal.pone.0037896.g005
Table 1. Effect of intraperitoneally administered BBG on animals cerebrally inoculated with Fukuoka-1 GSS strain.
Treatment Mice (diseased/inoculated) Mean incubation time (days 6 SD)
Vehicle 7/7 161.965.5
BBG (100 mg/kg) starting at 100 dpi 7/7 163.365.0
dpi: days post inoculation.
doi:10.1371/journal.pone.0037896.t001
BBG Prevents Prion Replication
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against prion diseases in vivo based on its anti-prion activity and the
neuroprotective effects of pharmacological antagonism of P2X7R
reported in several animal models of neurodegenerative diseases.
Unexpectedly, we demonstrated that BBG did not alleviate the
progression of prion diseases. Two possibilities may explain the
lack of neuroprotection following BBG administration, which was
intended to pharmacologically antagonize P2X7R. It is most likely
that activation of P2X7R plays an important role in neuroprotec-
tive effects under pathological conditions. Activation of P2X7R
increases the production of endocannabinoids in microglial cells
and astrocytes [13,14]. Sustained production of endocannabinoids
reduces the release of glutamate and cytotoxic agents from neuron
and microglia, respectively, and increases the release of growth
factors, leading to neuroprotection [52–54]. Indeed, activation of
cannabinoid receptors by cannabinoid derivatives mediates
neuroprotection in animal models of prion disease [55]. Thus, it
is conceivable that BBG might inhibit the neuroprotection
pathways involving P2X7R by antagonizing this receptor.
A second possible explanation for the lack of a protective effect
of BBG is that the effects of BBG may be attenuated by suppressed
microglial inflammatory responses in prion diseases. It is widely
accepted that over-activated microglia release potentially toxic
products, including reactive oxygen species, excitotoxin, and
proinflammatory cytokines such as interleukin (IL)-1b, IL-6, and
tumor necrosis factor-a, and the P2X7R system is essential for the
induction of microglial activation [9]. In the case of animal models
of prion disease, despite marked astrocytosis and microglial
activation, typical proinflammatory cytokine expression is absent
or low at the protein level [56–58] compared with those induced
by lipopolysaccharide. It has been proposed that such a suppressed
inflammatory response is mediated by the downregulation of
microglial responses by an antiinflammatory cytokine, such as
transforming growth factor-b1 [59]. In addition, prion induced-
glial cytokine responses are mainly mediated by astrocytes [56,57].
Taken together, we hypothesize that under such atypical in-
flammatory conditions characterized by restrained microglial
response, BBG cannot exert neuroprotective effects because these
effects have been attributed, at least in part, to its antiinflamma-
tory activity of blocking microglial P2X7R [21]. This hypothesis is
supported by previous results using an animal model of
Parkinson’s disease, where an atypical inflammatory response
was observed [60] and pharmacological blockade of P2X7R by
BBG and genetic deletion of this receptor had no protective effect
on dopaminergic neurons [61]. Whether atypical inflammatory
responses occurred in our mouse model of GSS remains to be
determined. In addition, more research will be required to assess
the correlation between the neuroprotective efficacy and antiin-
flammatory ability of BBG.
The change of brain pathology following BBG administration
did not appear to relate to its potential toxicity of BBG. BBG is
a derivative of a commonly used blue food dye (FD&C blue No. 1)
and had been shown to be safe in healthy animals [62,63].
Furthermore, we preliminary compared levels of PrP, GFAP, Iba1
and synaptophysin between brains of mock-infected mice treated
with vehiclle or BBG (100 mg/kg, 3 times per week for 3 weeks).
No statistically significant differences in these protein levels
between vehicle and BBG treated animals were observed (data
not shown). These previous and our observations exclude the
possibility that the potential toxicity of BBG influenced brain
pathology in prion-diseased animals.
In summary, BBG prevented PrPres accumulation in both a cell
culture and a mouse model of prion disease. Although BBG
possessed anti-prion and highly selective P2X7R antagonistic
activities, it did not appear to ameliorate the disease progression.
This suggests that the observed P2X7R upregulation in the brains
of diseased mice may play a neuroprotective role in prion disease.
These results provide insight into the pathophysiology of prion
diseases and have important implications for the treatment of these
disorders. Despite the lack of a neuroprotective effect, BBG has
many therapeutic advantages, including anti-prion activity, low
toxicity, and permeability across blood–brain barrier. Therefore,
continued study of BBG as a potential anti-prion compound is
warranted, taking into consideration its antagonistic effect of
P2X7R. Combining BBG and cannabinoids may prove effective
in the treatment of prion-infected animals.
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